Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 5:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 7,051 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo- matched Clear all

Conditions: Chronic HBV Infection
Interventions: EDP-514, Placebo; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 11
States / cities: Coronado, California • Los Angeles, California • San Diego, California + 8 more

Conditions: Healthy Volunteers
Interventions: Glyburide, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 40 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Colon Cancer, Gastrointestinal Cancer
Interventions: PoZibio, Inert placebo; Dietary Supplement
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Tampa, Florida

Conditions: Pompe Disease
Interventions: S-606001, Placebo; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 9
States / cities: Irvine, California • Gainesville, Florida • Atlanta, Georgia + 6 more

Conditions: Chronic Heart Failure
Interventions: AZD5462, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 14
States / cities: Alexander City, Alabama • Northridge, California • Torrance, California + 11 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Placebo, Seralutinib, Generic Dry Powder Inhaler; Drug · Device
Lead sponsor: GB002, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 50
States / cities: Birmingham, Alabama • Fresno, California • Los Angeles, California + 40 more

Conditions: Endothelial Dysfunction, Vascular Diseases, Kidney Injury, Brain Disease, Vascular Inflammation
Interventions: Vericiguat, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Systemic Lupus Erythematosus
Interventions: N-acetylcysteine, Placebo; Drug
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 12
States / cities: Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 8 more

Conditions: Idiopathic Thrombocytopenic Purpura, Thrombocytopenia, Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP), Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP), Thrombocytopenic Purpura, Immune Thrombocytopenia
Interventions: Romiplostim, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 25
States / cities: Orange, California • San Diego, California • Washington D.C., District of Columbia + 21 more

Conditions: Liver Cirrhosis
Interventions: Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet), Zibotentan + placebo (placebo matching dapagliflozin tablet), Zibotentan + dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 3
States / cities: Englewood, Colorado • Charleston, South Carolina • San Antonio, Texas

Conditions: Non Alcoholic Steatohepatitis, Fibrosis
Interventions: Idebenone, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Redwood City, California • Stanford, California

Conditions: Multiple Sclerosis
Interventions: American ginseng extract HT-1001, placebo; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Exercise-induced Bronchospasm
Interventions: Vitamin C, Placebo; Dietary Supplement · Other
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Alzheimer's Disease
Interventions: Placebo, Idalopirdine; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 50 Years and older
Enrollment: 933 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 46
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 40 more

Conditions: Cold Agglutinin Disease
Interventions: sutimlimab (BIVV009), placebo; Drug
Lead sponsor: Bioverativ, a Sanofi company; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 14
States / cities: Tucson, Arizona • Los Angeles, California • Georgetown, District of Columbia + 10 more

Conditions: Multiple Sclerosis
Interventions: Ponesimod, Placebo; Drug · Other
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 26
States / cities: Birmingham, Alabama • Fresno, California • Pasadena, California + 22 more

Conditions: Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Fatty Liver, Non-Alcoholic Steatohepatitis
Interventions: Vitamin E [(all-rac)-α-tocopheryl acetate], Omega-3 fatty acid (DHA EE), Omega-3 fatty acid (DHA EE) & Vitamin E [(all-rac)-α-tocopheryl acetate], Placebo; Dietary Supplement · Combination Product · Other
Lead sponsor: Naga P. Chalasani; Other
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 15
States / cities: Chandler, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 10 more

Conditions: Nocturnal Vasomotor Symptoms
Interventions: SCE-B, Placebo; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 30 Years to 65 Years · Female only
Enrollment: 157 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 17
States / cities: Anaheim, California • Sacramento, California • San Diego, California + 14 more

Conditions: Postherpetic Neuralgia
Interventions: Z160, Placebo; Drug
Lead sponsor: Zalicus; Industry
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 53
States / cities: Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 50 more

Conditions: Cannabis Use Disorder, Attention-deficit/Hyperactivity Disorder
Interventions: Adderall-XR, Matched placebo; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Seasonal Influenza
Interventions: mRNA-1010, Placebo, Active Comparator; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 885 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 21
States / cities: Phoenix, Arizona • Tempe, Arizona • Colton, California + 17 more

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: OPDC-34712, Placebo, Stimulant Therapy; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 740 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 35
States / cities: Little Rock, Arkansas • Beverly Hills, California • Irvine, California + 32 more

Conditions: Schizophrenia
Interventions: ITI-214 Dose A, ITI-214 Dose B, ITI-214 Dose C, ITI-214 Dose D (Elderly), Placebo, ITI-214 Dose E, ITI-214 Dose F, ITI-214 Dose G, ITI-214 Dose H; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Glendale, California • New York, New York

Conditions: Genetic Obesity
Interventions: Setmelanotide, Placebo; Drug
Lead sponsor: Rhythm Pharmaceuticals, Inc.; Industry
Eligibility: 6 Years to 65 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 21
States / cities: Scottsdale, Arizona • Suwanee, Georgia • Worcester, Massachusetts + 16 more

Search by objective public record fields.

A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)

Glyburide Healthy Volunteer Study

Postbiotics for Mitigation of Postoperative Dysbiosis in Gastrointestinal Cancer Surgery

Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)

A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure

Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

SGC Stimulation, Perioperative Vascular Reactivity, and Organ Injury in Cardiac Surgery

Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine

Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients

A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK

Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis

American Ginseng Treatment for Multiple Sclerosis Related Fatigue

Vitamin C & Exercise Induced Bronchoconstriction (EIB)

Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil

A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion

Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)

Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD)

Study to Evaluate the Effects of Synthetic Conjugated Estrogens, B (SCE-B) on Nocturnal Vasomotor Symptoms in Postmenopausal Women

Efficacy and Safety Study of Z160 in Subjects With Postherpetic Neuralgia

Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder

A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults

Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder

Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia

DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway